Ferreira Juliano, Campos Maria M, Araújo Ronaldo, Bader Michael, Pesquero João B, Calixto João B
Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis SC, Brazil.
Neuropharmacology. 2002 Dec;43(7):1188-97. doi: 10.1016/s0028-3908(02)00311-8.
The mechanisms by which kinins induce hyperalgesia in the spinal cord were investigated by using B(1) or B(2) knockout mice in conjunction with kinin selective agonists and antagonists. The i.t. administration of the kinin B(2) receptor agonists, bradykinin (BK) or Tyr(8)-BK produced dose-related thermal hyperalgesia evaluated in the hot-plate test. BK-induced hyperalgesia was abolished by the B(2) receptor antagonist Hoe 140. The i.t. injection of the kinin B(1) receptor agonists, des-Arg(9)-bradykinin (DABK) or des-Arg(10)-kallidin (DAKD) also caused dose-related thermal hyperalgesia. Different from the B(2) agonists, the i.t. injection of DABK or DAKD caused a weak, but prolonged hyperalgesia, an effect that was blocked by the B(1) receptor antagonist des-Arg(9)-[Leu(8)]-bradykinin (DALBK). The i.t. injection of BK caused thermal hyperalgesia in wild-type mice (WT) and in the B(1) receptor knockout mice (B(1)R KO), but not in the B(2) receptor knockout mice (B(2)R KO). Similarly, the i.t. injection of DABK elicited thermal hyperalgesia in WT mice, but not in B(1)R KO mice. However, DABK-induced hyperalgesia was more pronounced in the B(2)R KO mice when compared with the WT mice. The i.t. injection of Hoe 140 or DALBK inhibited the second phase of formalin (F)-induced nociception. Furthermore, i.t. Hoe 140, but not DALBK, also inhibits the first phase of F response. Finally, the i.t. injection of DALBK, but not of Hoe 140, inhibits the long-term thermal hyperalgesia observed in the ipsilateral and in contralateral paws after intraplantar injection with complete Freund's adjuvant. These findings provide evidence that kinins acting at both B(1) and B(2) receptors at the spinal level exert a critical role in controlling the nociceptive processing mechanisms. Therefore, selective kinin antagonists against both receptors are of potential interest drugs to treat some pain states.
通过使用B(1)或B(2)基因敲除小鼠,结合激肽选择性激动剂和拮抗剂,研究了激肽在脊髓中诱导痛觉过敏的机制。在热板试验中评估,鞘内注射激肽B(2)受体激动剂缓激肽(BK)或Tyr(8)-BK可产生剂量相关的热痛觉过敏。BK诱导的痛觉过敏被B(2)受体拮抗剂Hoe 140消除。鞘内注射激肽B(1)受体激动剂去-Arg(9)-缓激肽(DABK)或去-Arg(10)-胰激肽(DAKD)也引起剂量相关的热痛觉过敏。与B(2)激动剂不同,鞘内注射DABK或DAKD引起的痛觉过敏较弱但持续时间较长,该效应被B(1)受体拮抗剂去-Arg(9)-[Leu(8)]-缓激肽(DALBK)阻断。鞘内注射BK在野生型小鼠(WT)和B(1)受体基因敲除小鼠(B(1)R KO)中引起热痛觉过敏,但在B(2)受体基因敲除小鼠(B(2)R KO)中未引起。同样,鞘内注射DABK在WT小鼠中引起热痛觉过敏,但在B(1)R KO小鼠中未引起。然而,与WT小鼠相比,DABK诱导的痛觉过敏在B(2)R KO小鼠中更明显。鞘内注射Hoe 140或DALBK抑制了福尔马林(F)诱导伤害感受的第二阶段。此外,鞘内注射Hoe 140而非DALBK也抑制了F反应的第一阶段。最后,鞘内注射DALBK而非Hoe 140抑制了足底注射完全弗氏佐剂后在同侧和对侧爪中观察到的长期热痛觉过敏。这些发现提供了证据,表明在脊髓水平作用于B(1)和B(2)受体的激肽在控制伤害感受处理机制中发挥关键作用。因此,针对这两种受体的选择性激肽拮抗剂是治疗某些疼痛状态的潜在有意义的药物。